Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 16;11:729230. doi: 10.3389/fonc.2021.729230

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Huang, Lai, Liao, Cai, Li, Meng, Wang, Mo and Qin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Relationship between ADAM12 expression and clinical indicators in patients with COAD. (A) Subgroup analysis of ADAM12 expression in COAD based on patient age. (B) Subgroup analysis of ADAM12 expression in COAD based on individual cancer stages. (C) Subgroup analysis of ADAM12 expression in COAD based on the TP53 mutation status. (D) Subgroup analysis of ADAM12 expression in COAD based on histological subtypes. (E) Subgroup analysis of ADAM12 expression in COAD based on patient race. (F) Subgroup analysis of ADAM12 expression in COAD based on patient weight. (G) Subgroup analysis of ADAM12 expression in COAD based on patient sex. (H) Subgroup analysis of ADAM12 expression in COAD based on nodal metastasis status. (I–L) Different ADAM12 expression levels in COAD based on PMS2, MSH2, MSH6, and MLH1, respectively.